Table 3. Clinicopathological characteristics by LVSI status after propensity score matching.
| Characteristic | LVSI negative (n=58) | LVSI positive (n=71) | p value | ||
|---|---|---|---|---|---|
| Age | 58.55±9.82 | 56.42±8.39 | 0.187 | ||
| BMI (kg/m2) | 25.97±4.32 | 25.70±3.68 | 0.703 | ||
| Gravidity | 2.57±1.61 | 2.37±1.52 | 0.477 | ||
| Parity | 1.59±1.21 | 1.40±0.92 | 0.327 | ||
| Diabetes history | 0.677 | ||||
| No | 38 (65.52) | 44 (61.97) | |||
| Yes | 20 (34.48) | 27 (38.03) | |||
| Hypertension history | 0.172 | ||||
| No | 29 (50.00) | 44 (61.97) | |||
| Yes | 29 (50.00) | 27 (38.03) | |||
| Familial tumor history | 0.144 | ||||
| No | 43 (74.14) | 60 (84.51) | |||
| Yes | 15 (25.86) | 11 (15.49) | |||
| Pre-surgery CA125 (U/mL) | 59.18±69.93 | 53.82±111.61 | 0.770 | ||
| Pre-surgery CA19-9 (U/mL) | 51.63±50.57 | 35.05±65.52 | 0.193 | ||
| Stage | 0.593 | ||||
| Early (I–II) | 40 (68.97) | 52 (73.24) | |||
| Advanced (III–IV) | 18 (31.03) | 19 (26.76) | |||
| Grade | 0.490 | ||||
| 1 | 14 (24.14) | 11 (15.49) | |||
| 2 | 26 (44.83) | 38 (53.52) | |||
| 3 | 18 (31.03) | 22 (30.99) | |||
| Tumor diameter (cm) | 4.67±3.36 | 3.84±2.44 | 0.117 | ||
| Peritoneal cytology | 0.303 | ||||
| Negative | 45 (86.54) | 50 (94.34) | |||
| Positive | 7 (13.46) | 3 (5.66) | |||
| Lymph node status | 0.943 | ||||
| Negative | 45 (77.59) | 50 (78.13) | |||
| Positive | 13 (22.41) | 14 (21.88) | |||
| Myometrial invasion | 0.530 | ||||
| <50% | 27 (46.55) | 37 (52.11) | |||
| ≥50% | 31 (53.45) | 34 (47.89) | |||
| Cervical stromal invasion | 0.308 | ||||
| No | 44 (75.86) | 59 (83.10) | |||
| Yes | 14 (24.14) | 12 (16.90) | |||
| Adnexal involvement | 1.000 | ||||
| No | 55 (94.83) | 68 (95.77) | |||
| Yes | 3 (5.17) | 3 (4.23) | |||
| Surgical specimen IHC | |||||
| ER | 0.546 | ||||
| Negative | 8 (13.79) | 7 (10.29) | |||
| Positive | 50 (86.21) | 61 (89.71) | |||
| PR | 0.411 | ||||
| Negative | 5 (8.62) | 9 (13.24) | |||
| Positive | 53 (91.38) | 59 (86.76) | |||
| P53 | 0.603 | ||||
| Negative | 19 (35.85) | 21 (31.34) | |||
| Positive | 34 (64.15) | 46 (68.66) | |||
| Ki67 (%) | 36.82±23.97 | 41.89±17.96 | 0.241 | ||
| Adjuvant therapy use | 0.691 | ||||
| No | 10 (17.24) | 14 (20.00) | |||
| Yes | 48 (82.76) | 56 (80.00) | |||
The values are presented as mean±standard deviation, or number (%), unless otherwise indicated.
BMI, body mass index; CA, carbohydrate antigen; ER, estrogen receptor; IHC, immunohistochemistry; LVSI, lymphovascular space invasion; PR, progesterone receptor.